The European Biotech market is extremely dynamic, acknowledged as being number two in the world of market rankings. This is a cause for celebration!
After having set up a R&D hub for the biomanufacturing of clinical trial supplies in Gdansk, Polpharma is expanding its European footprint with a €100m investment in Warsaw. Several take-overs previously made the company a one-stop shop for biomanufacturing. European Biotechnology spoke with Federico Pollano, Director Contract Manufacturing and Business Development at the CDMO and biosimilars maker, about Polpharma’s strategy and expansion of biologics production.
On 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
EuropaBio has developed recommendations for changes to the Summary of Product Characteristics (SmPC) of biosimilars that would result in an enhanced level of transparency for the label.
We are living in a world of cutting-edge science, which holds the potential to transform the landscape for patients living with common and rare diseases within the next five years. This is of particular importance as we face a demographic evolution that will see an already-aging population expand significantly and rapidly across the globe.
Spanish Capital Cell was one of the first equity crowdfunding platforms that specialised in life sciences and biotech projects in Europe. In March, the group raised more than €1m through funding through the Spanish biotech campaign Bionure a new record. EuroBiotech talked to Capital Cell founder Daniel Oliver about their recent expansion into the UK and the development of the European life sciences crowdfunding scene.
Bayer has always been extremely supportive of the new Unitary Patent System (UPS) and has been one of the driving forces behind it within the German industry. However, the company will not be putting its full portfolio through the UPS and the Unified Patent Court (UPC).
Established in 2013, Polpharma Biologics is the biotechnology unit of the rapidly growing Polpharma Group one of the largest pharmaceutical players in the CEE region. Currently, with over 140 people, four sites, and full expertise for biopharmaceutical development and production, Polpharma Biologics is running five projects dedicated to monoclonal antibodies, and is just stepping into the contract development and manufacturing business.
Small companies and academic institutions develop their assets, in most cases, under budget constraints. Still, they have to meet the expectations of future strategic partners or investors in order to be an attractive option for them and to have a chance to get the product onto the market.
In December 2016, US biotech company Ionis Pharmaceuticals’ drug Spinraza received regulatory approval in the US. No doubt: the antisense technology behind Spinraza could be the next big thing